ProBioGen and Merus Sign Deal on GlymaxX® ADCC Enhancement Technology

News   Mar 05, 2014

 
ProBioGen and Merus Sign Deal on GlymaxX® ADCC Enhancement Technology
 
 
 

RELATED ARTICLES

Vaccines Are Not Protecting Farmed Fish From Disease

News

The vaccines used by commercial fish farmers are not protecting fish from disease, according to a new study. It showed vaccinated fish tend to show more symptoms when contracting diseases, with the health impacts and ultimately deaths occurring as if they’d never received a vaccine.

READ MORE

Uniqsis Reports on Expansion

News

Uniqsis reports following excellent business growth in 2017 that it has recruited a further sales / support specialist to be located at its office in Cambridge.

READ MORE

New Rare Antibody Isolation Strategy

News

A strategy for rapidly isolating rare, naturally occurring antibodies is reported this week. The strategy could aid in developing biological therapeutics and vaccines in the future.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Biopharma Cell Science Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE